Gilead Sciences Currently Up Eight Consecutive Days, on Pace for Longest Winning Streak Since July 2023 — Data Talk
Gilead Sciences, Inc. (GILD) is currently at $78.76, up $1.76 or 2.29%
--Would be highest close since Jan. 29, 2024, when it closed at $79.07
--On pace for largest percent increase since July 25, 2024, when it rose 4.1%
--Currently up 11 of the past 12 days
--Currently up eight consecutive days; up 6.75% over this period
--Longest winning streak since July 21, 2023, when it rose for 10 straight trading days
--Best eight day stretch since the eight days ending Aug. 2, 2024, when it rose 7.87%
--Up 3.55% month-to-date
--Down 2.78% year-to-date
--Down 35.55% from its all-time closing high of $122.21 on June 23, 2015
--Up 1.42% from 52 weeks ago (Aug. 30, 2023), when it closed at $77.66
--Down 9.77% from its 52-week closing high of $87.29 on Jan. 19, 2024
--Up 24.72% from its 52-week closing low of $63.15 on June 18, 2024
--Traded as high as $79.45; highest intraday level since Jan. 29, 2024, when it hit $80.00
--Up 3.18% at today's intraday high; largest intraday percent increase since July 25, 2024, when it rose as much as 5.22%
--Fourth best performer in the S&P 500 today
--Best performer in the Nasdaq 100 today
All data as of 11:09:03 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 28, 2024 11:26 ET (15:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks